Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264–79.
Article PubMed PubMed Central Google Scholar
Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409–36.
Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21.
Article CAS PubMed Google Scholar
Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57.
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.
Article CAS PubMed Google Scholar
Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197–208.
Article CAS PubMed Google Scholar
Yu YY, Zhu YJ, Xiao ZZ, Chen YD, Chang XS, Liu YH, et al. The pivotal application of patient-derived organoid biobanks for personalized treatment of gastrointestinal cancers. Biomark Res. 2022;10(1):73.
Article PubMed PubMed Central Google Scholar
Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81–94.
Article CAS PubMed Google Scholar
Di Capua D, Bracken-Clarke D, Ronan K, Baird AM, Finn S. The liquid biopsy for lung cancer: state of the art, limitations and future developments. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13163923.
Deng Z, Wu S, Wang Y, Shi D. Circulating tumor cell isolation for cancer diagnosis and prognosis. EBioMedicine. 2022;83: 104237.
Article CAS PubMed PubMed Central Google Scholar
Hong X, Roh W, Sullivan RJ, Wong KHK, Wittner BS, Guo H, et al. The lipogenic regulator SREBP2 induces transferrin in circulating melanoma cells and suppresses ferroptosis. Cancer Discov. 2021;11(3):678–95.
Article CAS PubMed Google Scholar
Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A, et al. Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med. 2014;6(11):1371–86.
Article CAS PubMed PubMed Central Google Scholar
Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158(5):1110–22.
Article CAS PubMed PubMed Central Google Scholar
Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 2019;25(14):4255–63.
Article CAS PubMed Google Scholar
Stergiopoulou D, Markou A, Strati A, Zavridou M, Tzanikou E, Mastoraki S, et al. Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer. Sci Rep. 2023;13(1):1258.
Article CAS PubMed PubMed Central Google Scholar
Pei H, Li L, Han Z, Wang Y, Tang B. Recent advances in microfluidic technologies for circulating tumor cells: enrichment, single-cell analysis, and liquid biopsy for clinical applications. Lab Chip. 2020;20(21):3854–75.
Article CAS PubMed Google Scholar
Connal S, Cameron JM, Sala A, Brennan PM, Palmer DS, Palmer JD, et al. Liquid biopsies: the future of cancer early detection. J Transl Med. 2023;21(1):118.
Article PubMed PubMed Central Google Scholar
Edsjo A, Holmquist L, Geoerger B, Nowak F, Gomon G, Alix-Panabieres C, et al. Precision cancer medicine: concepts, current practice, and future developments. J Intern Med. 2023;294(4):455–81.
Article CAS PubMed Google Scholar
He S, Yu S, Wei J, Ding L, Yang X, Wu Y. New horizons in the identification of circulating tumor cells (CTCs): an emerging paradigm shift in cytosensors. Biosens Bioelectron. 2022;203: 114043.
Article CAS PubMed Google Scholar
Chiang PJ, Xu T, Cha TL, Tsai YT, Liu SY, Wu ST, et al. Programmed cell death ligand 1 expression in circulating tumor cells as a predictor of treatment response in patients with urothelial carcinoma. Biology. 2021. https://doi.org/10.3390/biology10070674.
Article PubMed PubMed Central Google Scholar
Troncarelli Flores BC, Souza ESV, Ali Abdallah E, Mello CAL, Gobo Silva ML, Gomes Mendes G, et al. Molecular and kinetic analyses of circulating tumor cells as predictive markers of treatment response in locally advanced rectal cancer patients. Cells. 2019;8(7):641.
Article PubMed PubMed Central Google Scholar
He K, Baniasad M, Kwon H, Caval T, Xu G, Lebrilla C, et al. Decoding the glycoproteome: a new frontier for biomarker discovery in cancer. J Hematol Oncol. 2024;17(1):12.
Article CAS PubMed PubMed Central Google Scholar
Lei Y, Sun N, Zhang G, Liu C, Lu Z, Huang J, et al. Combined detection of aneuploid circulating tumor-derived endothelial cells and circulating tumor cells may improve diagnosis of early stage non-small-cell lung cancer. Clin Transl Med. 2020;10(3): e128.
Article PubMed PubMed Central Google Scholar
Ronzoni M, Manzoni M, Mariucci S, Loupakis F, Brugnatelli S, Bencardino K, et al. Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol. 2010;21(12):2382–9.
Article CAS PubMed Google Scholar
Liu Z, Wang Y, Shan F, Ying X, Zhang Y, Li S, et al. Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment. BMC Gastroenterol. 2021;21(1):283.
Article CAS PubMed PubMed Central Google Scholar
Machida M, Ambo M, Mishina R, Hada N, Tachibana F, Yamashita M, et al. Integrated predictors by propensity scoring with tumor markers and plasma levels of microRNA-21-5p, IL-17, and IL-10 complement early detection of hepatocellular carcinoma in patients with liver cirrhosis. Technol Cancer Res Treat. 2023. https://doi.org/10.1177/15330338231212084.
Article PubMed PubMed Central Google Scholar
Salehi M, Lavasani ZM, Keshavarz Alikhani H, Shokouhian B, Hassan M, Najimi M, et al. Circulating tumor cells as a promising tool for early detection of hepatocellular carcinoma. Cells. 2023. https://doi.org/10.3390/cells12182260.
Article PubMed PubMed Central Google Scholar
Wang HT, Bai LY, Wang YT, Lin HJ, Yang HR, Hsueh PR, et al. Circulating tumor cells positivity provides an early detection of recurrence of pancreatic cancer. J Formos Med Assoc. 2023;122(7):653–5.
Feng Z, Wu J, Lu Y, Chan YT, Zhang C, Wang D, et al. Circulating tumor cells in the early detection of human cancers. Int J Biol Sci. 2022;18(8):3251–65.
Comments (0)